<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Cognition Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/cognition-therapeutics-inc</link>
<description>Latest news and press releases for Cognition Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 07 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/cognition-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835550a78dffbe2df0e9267.webp</url>
<title>Cognition Therapeutics Inc</title>
<link>https://6ix.com/company/cognition-therapeutics-inc</link>
</image>
<item>
<title>Cognition Therapeutics to Present at Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-to-present-at-needham-virtual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-to-present-at-needham-virtual-healthcare-conference</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>PURCHASE, N.Y., April 07, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat</description>
</item>
<item>
<title>Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update</title>
<link>https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-reports-year-end-2025-financial-results-and-provides-clinical-development-update</link>
<guid isPermaLink="true">https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-reports-year-end-2025-financial-results-and-provides-clinical-development-update</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>-Advancing zervimesine clinical development in DLB psychosis – - Meeting with FDA Division of Psychiatry expected by mid-2026 -- Management conference call at</description>
</item>
<item>
<title>Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results</title>
<link>https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-to-report-fourth-quarter-and-year-end-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-to-report-fourth-quarter-and-year-end-2025-financial-results</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>Conference Call and Live Webcast Scheduled for March 26, 2026 PURCHASE, N.Y., March 23, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX),</description>
</item>
<item>
<title>Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026</title>
<link>https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-presents-evidence-of-zervimesines-impact-on-neuropsychiatric-symptoms-of-dementia-with-lewy-bodies-at-adpd-2026</link>
<guid isPermaLink="true">https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-presents-evidence-of-zervimesines-impact-on-neuropsychiatric-symptoms-of-dementia-with-lewy-bodies-at-adpd-2026</guid>
<pubDate>Tue, 17 Mar 2026 11:30:00 GMT</pubDate>
<description>PURCHASE, N.Y., March 17, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented an analysis from the Phase 2 COG1201 SHIMMER study (NCT05225415) of zervimesine (CT1812) in dementia with Lewy bodies (DLB) at the AD/PD™ 2026 Alzheimer's & Parkinson's Diseases Conference. The conference is being conducted March 17-21, 2026 in Copenhagen, Denmark. The analysis f</description>
</item>
<item>
<title>Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis</title>
<link>https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-advancing-zervimesine-ct1812-for-dementia-with-lewy-bodies-dlb-psychosis</link>
<guid isPermaLink="true">https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-advancing-zervimesine-ct1812-for-dementia-with-lewy-bodies-dlb-psychosis</guid>
<pubDate>Mon, 02 Mar 2026 12:30:00 GMT</pubDate>
<description>We believe regulatory strategy expedites development of potential first treatment to address DLB psychosisPURCHASE, N.Y., March 02, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced plans to advance development of zervimesine for the treatment of dementia with Lewy bodies (DLB) psychosis, which impacts as many as 75% of patients. This follows receipt of fina</description>
</item>
<item>
<title>Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies</title>
<link>https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-extends-expanded-access-123000035</link>
<guid isPermaLink="true">https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-extends-expanded-access-123000035</guid>
<pubDate>Thu, 05 Feb 2026 12:30:00 GMT</pubDate>
<description>PURCHASE, N.Y., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, has extended the duration of the expanded access program (EAP) for dementia with Lewy bodies (DLB). The program, which was originally expected to provide each participant with twelve months of treatment, will now allow several more months of treatment. “The EAP has been running since June 2</description>
</item>
<item>
<title>Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies</title>
<link>https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-completes-type-c-123000398</link>
<guid isPermaLink="true">https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-completes-type-c-123000398</guid>
<pubDate>Tue, 27 Jan 2026 12:30:00 GMT</pubDate>
<description>PURCHASE, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, conducted a Type C meeting with the U.S. Food and Drug Administration (FDA) on January 21, 2026. The objective of this meeting was to review plans for the proposed Phase 2b study of zervimesine in dementia with Lewy bodies (DLB), a disease with no FDA-approved therapies. “We had a productive me</description>
</item>
<item>
<title>Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy Bodies</title>
<link>https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-publishes-phase-2-123000299</link>
<guid isPermaLink="true">https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-publishes-phase-2-123000299</guid>
<pubDate>Tue, 06 Jan 2026 12:30:00 GMT</pubDate>
<description>- Zervimesine exhibited meaningful improvement in behavioral, functional, cognitive, and movement measures compared to placebo -PURCHASE, N.Y., Jan. 06, 2026...</description>
</item>
<item>
<title>Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies</title>
<link>https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-reaches-full-enrollment-123000120</link>
<guid isPermaLink="true">https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-reaches-full-enrollment-123000120</guid>
<pubDate>Wed, 03 Dec 2025 12:30:00 GMT</pubDate>
<description>- Type C Meeting with U.S. Food and Drug Administration (FDA) Scheduled for Second Half of January -PURCHASE, N.Y., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that its expanded access program has reached full enrollment. Each of the individuals enrolled in the program are being treated with 100 mg of oral zervimesine daily for up to one y</description>
</item>
<item>
<title>Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference</title>
<link>https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-presents-phase-3-123000349</link>
<guid isPermaLink="true">https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-presents-phase-3-123000349</guid>
<pubDate>Mon, 01 Dec 2025 12:30:00 GMT</pubDate>
<description>- Seeking Alignment with European Medicines Agency (EMA) at February 2026 Meeting -- Actively Evaluating Strategy Across DLB and Alzheimer’s Disease - PURCHASE, N.Y., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented plans for a registrational program for zervimesine in mild-to-moderate Alzheimer's disease during the annual Clinical Trials on Alzhei</description>
</item>
<item>
<title>Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference</title>
<link>https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-participate-37th-annual-210100737</link>
<guid isPermaLink="true">https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-participate-37th-annual-210100737</guid>
<pubDate>Thu, 20 Nov 2025 21:01:00 GMT</pubDate>
<description>PURCHASE, N.Y., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, announced that the Company’s president and CEO, Lisa Ricciardi will participate in an “unplugged” fireside discussion at the annual Piper Sandler Healthcare Conference. The conference will take place December 2-4, 2025 at The Lotte New York Palace hotel. Details of Cognition’s fireside discussion are a</description>
</item>
<item>
<title>Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer’s Disease</title>
<link>https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-completes-enrollment-phase-123600217</link>
<guid isPermaLink="true">https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-completes-enrollment-phase-123600217</guid>
<pubDate>Thu, 13 Nov 2025 12:36:00 GMT</pubDate>
<description>Study conducted in collaboration with the Alzheimer’s Clinical Trials ConsortiumPURCHASE, N.Y., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the company has reached target enrollment of 540 participants in the randomized, placebo-controlled Phase 2 ‘START’ Study. A number of additional patients are in the final stages of screening and will</description>
</item>
<item>
<title>Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs</title>
<link>https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-reports-financial-results-123000900</link>
<guid isPermaLink="true">https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-reports-financial-results-123000900</guid>
<pubDate>Thu, 06 Nov 2025 12:30:00 GMT</pubDate>
<description>- $30 Million Registered Direct Offering Support Next Stage of Development for Zervimesine (CT1812) - - Aligned with U.S. FDA on Registrational Path for Zervimesine - - Expanded Access Program for Dementia with Lewy Bodies Ongoing - PURCHASE, N.Y., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today reported financial results for the third quarter ende</description>
</item>
<item>
<title>Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Reaches 75% Enrollment Target</title>
<link>https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-study-zervimesine-ct1812-113000957</link>
<guid isPermaLink="true">https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-study-zervimesine-ct1812-113000957</guid>
<pubDate>Wed, 03 Sep 2025 11:30:00 GMT</pubDate>
<description>PURCHASE, N.Y., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the Phase 2 ‘START’ Study has reached the 75% enrollment mark. The START Study is enrolling approximately 540 individuals with mild cognitive impairment (MCI) and early Alzheimer’s disease who will be treated with zervimesine (CT1812) or placebo for 18 months. Cognition is condu</description>
</item>
<item>
<title>Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)</title>
<link>https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-closes-30-million-200000007</link>
<guid isPermaLink="true">https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-closes-30-million-200000007</guid>
<pubDate>Tue, 02 Sep 2025 20:00:00 GMT</pubDate>
<description>PURCHASE, N.Y., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, closed its previously announced registered direct offering of 14,700,000 shares of common stock at a purchase price of $2.05 per share. Gross proceeds from the offering were approximately $30 million, before deducting placement agent fees and other offering expenses. Titan Partners Group,</description>
</item>
<item>
<title>Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock</title>
<link>https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-announces-30-million-005300531</link>
<guid isPermaLink="true">https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-announces-30-million-005300531</guid>
<pubDate>Thu, 28 Aug 2025 00:53:00 GMT</pubDate>
<description>- The offering was made to two new fundamental institutional investors - - The Company intends to use the net proceeds to fund preparation for our Phase 3 programs of zervimesine in neurodegenerative disorders - PURCHASE, N.Y., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today announced that it has entered into a securities purchase agreement for th</description>
</item>
<item>
<title>Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement</title>
<link>https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-regains-compliance-nasdaq-200000345</link>
<guid isPermaLink="true">https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-regains-compliance-nasdaq-200000345</guid>
<pubDate>Tue, 26 Aug 2025 20:00:00 GMT</pubDate>
<description>PURCHASE, N.Y., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, was notified by The Nasdaq Listing Qualifications Staff (“Nasdaq”) that the Company has regained compliance with the exchange’s continued listing standard for minimum share price under Rule 5550(a)(2) (the “Bid Price Rule”). To regain compliance with the Bid Price Rule, the Company's shares</description>
</item>
<item>
<title>Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer’s Disease</title>
<link>https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-receives-end-phase-200000670</link>
<guid isPermaLink="true">https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-receives-end-phase-200000670</guid>
<pubDate>Tue, 12 Aug 2025 20:00:00 GMT</pubDate>
<description>- Cognition and FDA align on enriched population, study design, and endpoints - PURCHASE, N.Y., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, received final minutes from the U.S. Food and Drug Administration (FDA) pertaining to the end-of-Phase 2 meeting that was conducted on July 9, 2025. FDA confirmed the proposed design of the Phase 3 program may suppo</description>
</item>
<item>
<title>Cognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs</title>
<link>https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-reports-financial-results-200000713</link>
<guid isPermaLink="true">https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-reports-financial-results-200000713</guid>
<pubDate>Thu, 07 Aug 2025 20:00:00 GMT</pubDate>
<description>- Discussed plans to support a pivotal Alzheimer’s disease program with FDA at end-of-phase 2 meeting - - Initiated expanded access program (EAP) for people with dementia with Lewy bodies (DLB) - - Surpassed 50% enrollment in Phase 2 ‘START’ study of zervimesine in early Alzheimer’s disease - PURCHASE, N.Y., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders</description>
</item>
<item>
<title>Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer’s Disease</title>
<link>https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-presents-data-aaic-113000568</link>
<guid isPermaLink="true">https://6ix.com/company/cognition-therapeutics-inc/news/cognition-therapeutics-presents-data-aaic-113000568</guid>
<pubDate>Tue, 29 Jul 2025 11:30:00 GMT</pubDate>
<description>- Zervimesine’s impact on debilitating DLB behavioral symptoms highlighted in podium presentation -- Plasma p-tau217 levels can identify Alzheimer’s patients most likely to benefit from zervimesine treatment -- Plasma and CSF biomarkers support zervimesine’s impact on Alzheimer’s disease biology - PURCHASE, N.Y., July 29, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorde</description>
</item>
</channel>
</rss>